Longeveron® Announces First Quarter 2025 Financial Results and Provides Business UpdateMIAMI, May 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (
NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today reported financial results for the quarter ended March 31, 2025 and provided a business update.
SHAREHOLDER ALERT: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Longeveron Inc. (LGVN)
Shareholder rights law firm Robbins LLP reminds investors of the class action filed on behalf of all persons and entities that purchased Longeveron Inc. (
NASDAQ: LGVN) Class A common stock pursuant to or traceable to the Company's February 12, 2021 initial public offering ("IPO"), or between February 12, 2021 and August 12, 2021. Longeveron is a clinical stage biotechnology company that engages in developing cellular therapies for aging-related and life-threatening conditions. The Company's lead investigational product is Lomecel-B, which is currently in Phase 2b of its trial ("Phase 2b Aging Frailty Trial").
